Swog Cancer Research Network

This study is testing which of two different chemotherapy combinations works better for people with advanced small bowel cancer that has stopped responding to previous treatments. The trial will compare two drug regimens to see which one better controls cancer growth and helps pa…

This trial is for people whose kidney cancer has spread. It aims to find out if removing the original kidney tumor with surgery, on top of standard immunotherapy drug combinations, helps patients live longer than using the drugs alone. About 364 participants will be randomly assi…

This large, phase 3 trial is comparing two chemotherapy approaches for early-stage triple-negative breast cancer. It aims to see if a shorter treatment that avoids a harsh drug called an anthracycline works as well as the standard, longer regimen. The study will enroll 2,400 part…

This study is for men with advanced prostate cancer that has spread and no longer responds to standard hormone-lowering treatments. It will test if adding a chemotherapy drug called carboplatin to the standard chemotherapy drug cabazitaxel works better than cabazitaxel alone. The…

This study is for adults newly diagnosed with AL amyloidosis, a disease where abnormal proteins damage organs like the heart and kidneys. It aims to find out if adding a stem cell transplant to a standard chemotherapy regimen works better than the chemotherapy regimen alone. Afte…

This study is for people with advanced pancreatic cancer that has stopped responding to their first treatment. It is testing if adding a targeted drug called panitumumab to standard second-line chemotherapy helps patients live longer than chemotherapy alone. The trial is specific…

This study is for people with advanced non-small cell lung cancer that has worsened after initial chemotherapy and immunotherapy. It compares the current standard two-drug treatment (docetaxel and ramucirumab) against that same treatment plus a third drug called cemiplimab, which…

This large study aims to find better treatments for people with advanced non-small cell lung cancer who have already tried standard therapies. Researchers will test patients' tumors for specific genetic markers, then assign them to different treatment groups based on those result…

This study is testing two different combinations of targeted drugs for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR and MET) and has stopped responding to a common treatment. The trial will compare whether adding a third drug (ramuciruma…

This study is testing whether taking two chemotherapy drugs (capecitabine and temozolomide) after surgery can prevent or delay the return of a rare type of pancreatic cancer called a neuroendocrine tumor in high-risk patients. About 141 adults who have recently had their tumor su…

This large study is testing whether adding surgery to remove the prostate or radiation therapy to standard drug treatments helps men with prostate cancer that has spread to other parts of the body live longer. It will enroll over 1,200 men who have already started standard hormon…

This study is testing if adding a second drug, ramucirumab, to the standard drug tepotinib works better for people with advanced non-small cell lung cancer that has a specific genetic change called a MET exon 14 skip. The goal is to see if the combination can better control the c…

This trial is testing which of two drug combinations works better for people with advanced melanoma that has spread to the brain. One group gets three drugs (encorafenib, binimetinib, nivolumab), while the other gets two drugs (ipilimumab, nivolumab). The main goal is to see whic…

This study is testing a new, injectable drug called amivantamab for people with advanced non-small cell lung cancer that has a specific genetic feature called MET amplification. The drug is designed to target and reduce the extra copies of the MET gene in the tumor, which may hel…

This study is testing whether adding one of two new drugs (tazemetostat or zanubrutinib) to an existing two-drug therapy works better for controlling an aggressive type of blood cancer called large B-cell lymphoma. It is for adults whose cancer has returned or did not respond to …

This study is testing if giving the chemotherapy drug carboplatin before surgery can help shrink tumors in men with high-risk prostate cancer who have specific inherited BRCA gene mutations. The goal is to see if this approach leads to better outcomes by reducing or eliminating c…

This study aims to protect the hearts of people with advanced HER2-positive breast cancer who are receiving a specific treatment (trastuzumab) that can sometimes damage the heart. It is observing nearly 500 patients to see how common heart problems are and testing if a common hea…

This study is for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatments. After receiving a standard CAR T-cell therapy, patients whose cancer is still present but stable will be assigned to receive one of two additional drugs, both drugs, o…

This study is testing a free, web-based education program called Current Together After Cancer (CTAC). It aims to help people who have had surgery for stage II or III colorectal cancer get the recommended follow-up tests and scans. The program provides information and support to …

This Phase 2 trial tests whether personalized maintenance treatments can better control extensive stage small cell lung cancer. Researchers will analyze tumor tissue from 900 patients to match them to one of three treatment groups based on their cancer's specific features. After …

This study is testing whether giving a single injection of the drug lanreotide before pancreas removal surgery can prevent a serious complication called a pancreatic fistula. A fistula is a leak from the pancreas that can cause infection and longer hospital stays. Researchers are…

This study aims to understand why some cancer patients develop serious side effects from immunotherapy drugs while others don't. Researchers will follow 2,062 patients with solid tumors who are starting standard immunotherapy treatment. By tracking side effects, collecting blood …